4.4 Article

Effects of immediate or early oral feeding on acute pancreatitis: A systematic review and meta-analysis

Journal

PANCREATOLOGY
Volume 22, Issue 2, Pages 175-184

Publisher

ELSEVIER
DOI: 10.1016/j.pan.2021.11.009

Keywords

Mild acute pancreatitis; Moderate acute pancreatitis; Immediate or early oral refeeding; Delayed oral refeeding; Timing

Funding

  1. National Natural Science Foundation of China [81860123]

Ask authors/readers for more resources

This meta-analysis suggests that immediate or early oral feeding can reduce length of stay and costs in mild to moderate AP without increasing adverse events.
Background: The timing of oral refeeding can affect length of stay (LOS) and recovery of acute pancreatitis (AP). However, the optimal timing for oral refeeding is still controversial for AP. This meta-analysis investigated the effects of immediate or early versus delayed oral feeding on mild and moderate AP, regardless of improvement in clinical signs or laboratory indicators. Methods: This systematic review and meta-analysis of randomized controlled trials (RCTs) based on data from Embase, Cochrane Library, PubMed, Web of science, and CBM before August 2021. Two researchers independently used Stata16 to extract and analyse study data. Random effect model was performed for meta-analysis to calculate the risk ratio (RR) and standardized mean difference (SMD). Results: 8 RCTs were selected, including 748 patients with mild to moderate AP. Patients in IOR (Immediate or early Oral Refeeding) group had less costs [SMD-0.83, 95%CI (-1.17,-0.5), P < 0.001] and shorter LOS [SMD-1.01, 95%CI (-1.17,-0.85), P < 0.001] than the DOR (Delayed Oral Refeeding) group patients. However, there was no difference in mortality [RR 0.54, 95%CI (0.11, 2.62), P = 0.44], pain relapse rate [RR 0.58, 95%CI (0.25, 1.35), P = 0.27], feeding intolerance rate [RR 0.61, 95%CI (0.28, 1.3), P = 0.2], AP progression rate [RR 0.21, 95%CI (0.04, 1.07), P = 0.06] and overall complications rate [RR 0.41, 95%CI (0.17, 1.01), P = 0.05] between the IOR and DOR groups. Conclusions: Limited data suggest that IOR could reduce LOS and costs without increasing adverse events in mild to moderate AP. (c) 2021 The Authors. Published by Elsevier B.V. on behalf of IAP and EPC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available